First Personalized Gene Therapy Using Base Editing Shows Promising Results in Baby with Rare Disorder
- Researchers reported that KJ Muldoon, a baby from Pennsylvania, is thriving after receiving a personalized gene editing therapy in 2025.
- KJ was identified soon after birth as having a severe form of CPS1 deficiency, a rare genetic disorder that proves fatal for half of affected infants if left untreated.
- A specialized team from a leading pediatric research center and a major academic medical institution developed a tailored CRISPR-based treatment, delivered through lipid nanoparticles, to fix his defective gene.
- KJ received initial and follow-up doses between February and April, with noted improvements in eating and recovering from illnesses; his mother called every milestone "a big moment for us."
- Experts say this case marks a first step toward broader gene editing treatments for rare diseases, though similar personalized therapies may take years to become widely available.
255 Articles
255 Articles
Experimental gene editing helped a desperately ill baby thrive. Scientists say it could someday treat millions
Though it may be a while before similar personalized treatments are available for others, doctors hope the technology can someday help millions who have been left behind by genetic medicine because their diseases are so rare.
Washington Should Fund More Potential Science Miracles
A baby boy, born in Philadelphia in 2024 with a potentially fatal genetic deficiency, has become the first person treated with a custom gene-editing therapy. Doctors used CRISPR technology to rapidly create a personalized treatment for KJ, targeting the child’s specific mutation. The boy is meeting developmental milestones, his weight is in the 40th percentile, but his need for a liver transplant is still unknown, according to news reports. This…
From birth to gene-edited in 6 months: Custom therapy breaks speed limits
News broke yesterday that researchers in Philadelphia appear to have successfully treated a 6-month-old baby boy, called KJ, with a personalized CRISPR gene-editing therapy. The treatment corrects an ultra-rare mutation in KJ that breaks a liver enzyme. That enzyme is required to convert ammonia, a byproduct of metabolism, to urea, a waste product released in urine. Without treatment, ammonia would build up to dangerous levels in KJ—and he would…
Coverage Details
Bias Distribution
- 61% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage